CUVL revenueFY2026$64.32M
- FY YoY
- +5.2%
CUVL revenue was $64.32M for fiscal 2026 (ended Jun 30, 2026), up 5.2% from fiscal 2025.
Clinuvel Pharmaceuticals Limited (CUVL) financials
For fiscal 2026 (ended Jun 30, 2026), Clinuvel Pharmaceuticals Limited reported $64.32M of revenue and $23.18M of net income.
- Revenue, FY2026
- $64.32M
- Revenue growth, YoY
- +5.2%
- Net income, FY2026
- $23.18M
- Net income growth, YoY
- +0.2%
- Net margin
- 36.0%
- Free cash flow, FY2026
- $11.85M
- EPS, diluted, FY2026
- $0.46
- EPS growth, YoY
- +0.0%
- Cash
- $13.91M
- P/E
- 11.10
- P/S
- 4.00
- Market cap
- $257.2M
FY2024FY2026
FY2024FY2026
FY2024FY2026
CUVL revenue and earnings growth
CUVL net incomeFY2026$23.18M
- FY YoY
- +0.2%
CUVL net income was $23.18M for fiscal 2026 (ended Jun 30, 2026), up 0.2% from fiscal 2025.
CUVL EPSFY2026$0.46
- FY YoY
- +0.0%
CUVL diluted EPS was $0.46 for fiscal 2026 (ended Jun 30, 2026), up 0.0% from fiscal 2025.
CUVL free cash flowFY2026$11.85M
- FY YoY
- -56.3%
CUVL free cash flow was $11.85M for fiscal 2026 (ended Jun 30, 2026), down 56.3% from fiscal 2025.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Revenue | $64.32M | $61.12M | $57.91M |
| Cost of revenue | $10.98M | $11.51M | $10.74M |
| Gross profit | $53.34M | $49.61M | $47.17M |
| Research and development | $12.23M | $13.22M | $9.99M |
| Selling, general and admin | $7.38M | $6.68M | $6.81M |
| Operating income | $27.92M | $26.52M | $28.53M |
| Pre-tax income | $32.72M | $33.09M | $33.22M |
| Income tax | $9.54M | $9.97M | $9.87M |
| Net income | $23.18M | $23.12M | $23.35M |
| EPS, basic | $0.46 | $0.46 | $0.47 |
| EPS, diluted | $0.46 | $0.46 | $0.46 |
| Diluted shares | 50.7M | 50.4M | 51.0M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Cash and equivalents | $13.91M | $18.06M | - |
| Short-term investments | $160.10M | $127.46M | - |
| Receivables | $16.19M | $17.75M | $17.51M |
| Inventory | $4.76M | $5.73M | - |
| Current assets | $196.53M | $170.70M | - |
| Total assets | $203.98M | $176.74M | - |
| Current liabilities | $13.35M | $17.63M | - |
| Total liabilities | $15.36M | $20.00M | - |
| Shareholders' equity | $188.62M | $156.74M | $135.03M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Operating cash flow | $12.91M | $27.30M | $23.75M |
| Capital expenditures | $1.06M | $190.6K | $3.65M |
| Free cash flow | $11.85M | $27.10M | $20.10M |
| Investing cash flow | -$25.64M | -$30.62M | -$19.25M |
| Financing cash flow | -$1.67M | -$1.87M | -$2.09M |
| Dividends paid | $1.67M | $1.69M | $1.59M |
| Share repurchases | - | $174.0K | $497.7K |
| Stock-based compensation | $1.59M | $1.30M | $4.07M |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
|---|---|---|---|
| Revenue growth, YoY | 5.2% | 5.5% | - |
| Net income growth, YoY | 0.2% | -1.0% | - |
| EPS growth, YoY | 0.0% | 0.0% | - |
| Gross margin | 82.9% | 81.2% | 81.5% |
| Operating margin | 43.4% | 43.4% | 49.3% |
| Net margin | 36.0% | 37.8% | 40.3% |
| Free cash flow margin | 18.4% | 44.3% | 34.7% |
| Return on equity | 12.3% | 14.8% | 17.3% |
| Return on assets | 11.4% | 13.1% | - |
| Current ratio | 14.72 | 9.68 | - |
Source: XBRL data Clinuvel Pharmaceuticals Limited files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
CUVL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CUVL | $64.32M | +5.2% | $23.18M | 36.0% | $257.2M |
| FERG | $30.76B | +3.8% | $1.86B | 6.0% | $45.21B |
| CDTG | $18.23M | -38.8% | -$10.20M | -55.9% | $2.7M |
| DXST | $12.95M | +12.2% | -$322.2K | -2.5% | $2.1M |
CUVL FAQ
9 questionsWhat is CUVL revenue?
Clinuvel Pharmaceuticals Limited (CUVL) reported $64.32M of revenue for fiscal 2026 (ended Jun 30, 2026). That is up 5.2% from the year before.Is CUVL profitable?
Yes. Clinuvel Pharmaceuticals Limited earned $23.18M in net income for fiscal 2026 (ended Jun 30, 2026), a net margin of 36.0%.How much cash and debt does CUVL have?
Clinuvel Pharmaceuticals Limited reported $13.91M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is CUVL revenue growing?
Clinuvel Pharmaceuticals Limited's revenue changed +5.2% in fiscal 2026, to $64.32M.What is CUVL gross margin?
Clinuvel Pharmaceuticals Limited's gross profit was $53.34M on $64.32M of revenue for fiscal 2026 (ended Jun 30, 2026), a gross margin of 82.9%.What is CUVL free cash flow?
Clinuvel Pharmaceuticals Limited generated $11.85M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of $12.91M less capital expenditures.What is CUVL earnings per share?
Diluted earnings per share were $0.46 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did CUVL last report financial results?
The latest statements here come from Clinuvel Pharmaceuticals Limited's 20-F filed on Oct 30, 2026, covering the period ended Jun 30, 2026.Where does this CUVL financial data come from?
Quantisnow builds these statements from the structured XBRL data Clinuvel Pharmaceuticals Limited files with the SEC. It is provided for information only and is not investment advice.